Cancer is a complex disease driven by somatic mutations accumulating within a cell, leading to uncontrolled proliferation and metastasis.  Recent advances in next-generation sequencing (NGS) technologies have revolutionized our understanding of the genetic basis of cancer, enabling comprehensive genomic profiling of individual tumors. This has facilitated the identification of numerous driver mutations and actionable genetic alterations, paving the way for personalized medicine approaches.  Advances include the development of targeted therapies, such as tyrosine kinase inhibitors (TKIs) for specific oncogenic mutations, and immunotherapies, like checkpoint inhibitors, harnessing the patient's own immune system.  Liquid biopsies, employing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), offer minimally invasive methods for monitoring disease progression and treatment response.  However, challenges remain, including the heterogeneity of tumors, the development of drug resistance, and the identification of biomarkers predictive of response to specific therapies.  Ongoing research focuses on integrating multi-omics data, including genomics, transcriptomics, and proteomics, to refine risk stratification, improve treatment selection, and ultimately enhance cancer patient outcomes.  The future of cancer treatment hinges on continued development and refinement of these personalized medicine strategies.